ArticleIranian journal of pharmaceutical research : IJPR
Nrf2/BAX/Bcl2 Signaling Crosstalk and Histopathological Correlates of Renoprotection by Black Soldier Fly Larval Oil Against Aflatoxin B1-Induced Oxidative and Inflammatory Kidney Injury in Rats.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aflatoxin B1 (AFB1) is a highly hazardous mycotoxin commonly detected in contaminated food supplies and poses serious health risks to both humans and animals. Although its hepatotoxic effects are well established, the kidney, a principal organ for toxin elimination, remains highly susceptible to AFB1-induced injury through mechanisms involving oxidative stress, inflammatory responses, and apoptotic cell death. Black soldier fly larvae (BSFL) oil, characterized by a high content of medium-chain fatty acids and other bioactive lipids, represents a sustainable and promising source of naturally derived antioxidant and anti-inflammatory agents. Objectives: This study aimed to evaluate the renoprotective potential of the n-hexane BSFL extract against AFB1-induced nephrotoxicity in a rat model, with particular emphasis on elucidating the involvement of Nrf2-driven antioxidant pathways and BAX/Bcl2-regulated apoptotic signaling. Methods: Thirty-five male Wistar rats were allocated to five experimental groups: control, AFB1 (75 µg/kg), BSFL (360 mg/kg), AFB1 + BSFL180, and AFB1 + BSFL360. After a 28-day treatment period, renal function indicators (BUN, creatinine, uric acid), oxidative stress markers (MDA, SOD, CAT, GSH), inflammatory cytokines (TNF-α, IL-6, NF-κB), and apoptosis-related proteins (Nrf2, BAX, Bcl2) were evaluated. Histopathological assessments were also performed to examine tubular necrosis, glomerular damage, and inflammatory infiltration. Results: AFB1 exposure resulted in marked increases in BUN, creatinine, uric acid, MDA, TNF-α, IL-6, NF-κB, and BAX levels, along with significant decreases in SOD, CAT, GSH, Nrf2, and Bcl2 (P < 0.001). Co-administration of BSFL extract, particularly at the higher dose (360 mg/kg), effectively reversed these alterations and restored the BAX/Bcl2 ratio toward normal values. Histological examination corroborated these biochemical improvements by showing reduced tubular necrosis, glomerular injury, and inflammatory cell infiltration in the extract-treated groups. Conclusions: These findings indicate that BSFL extract confers substantial renoprotection against AFB1-induced kidney injury through the coordinated regulation of Nrf2-mediated antioxidant defense and BAX/Bcl2-dependent apoptotic pathways. The absence of intrinsic toxicity, together with the sustainable and eco-friendly production of BSFL oil, underscores its potential as a promising natural therapeutic candidate for mitigating mycotoxin-associated nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.